The fight against vaccine shortages is slowly improving. Now the Tübingen company Curevac is also entering the approval process.
The company announced on Friday morning that the responsible European Medicines Agency (EMA) had received the first results as part of a rolling process.
The companies continuously hand over data to the supervisory authorities during their ongoing studies instead of collecting them and only handing them over at the end.
The key results from the ongoing Phase III study should be available to the EMA by the beginning of April, a spokesman told Merkur.de on Friday. According to earlier information, Curevac is hoping for approval of its vaccine candidate in the second quarter.
So far, the Covid-19 vaccines from Biontech and its partner Pfizer, Moderna and AstraZenaca have been approved within the EU. A rolling approval process for another possible vaccine from the US manufacturer Novavax is currently in progress.
The US pharmaceutical giant applied for emergency approval in the USA at the beginning of February. Another corona vaccine could now follow in the EU with Curevac.
Curevac: Vaccine production is already in full swing
At the Tübingen company, production of the new vaccine candidate is already in full swing. In order to further increase capacities, Curevac wants to work with other companies, including Bayer, Wacker Chemie and Fareva.
The company is also building a completely new production facility at its headquarters. It is scheduled to start operating in 2022.
Similar to the Mainz competitor Biontech Curevac has also focused on the development of messenger nucleic acids (mRNA) specialized. In this novel approach, messengers are supposed to bring genetic blueprints for the production of unimaginably tiny amounts of antigens into the cells.
The proteins produced are supposed to trigger a defense reaction of the immune system, which the body then also against viruses such as the coronavirus SARS-CoV-2 should protect. According to Curevac, the first interim results indicate a “very high effectiveness”. In addition, the requirements for cooling are apparently considerably lower than those of Biontech, for example. *Merkur.de is part of the Ippen Digital network.
[ source link ]
Curevac starts approval process Covid vaccine production full swing